Type 2 & other diabetes

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis

Cardiovasc DiabetolPublished Systematic review and meta-analysis of randomised trials and propensity score-matched observational studies

Pooled result · All-cause mortalityResult — go to the resultHazard ratio 0.79 95% CI 0.68–0.91

Authors' conclusion

In this meta-analysis, early and delayed treatment with SGLT2 inhibitors following MI was associated with a significant reduction in all-cause mortality. Furthermore, the presence of T2DM was associated with a greater mortality reduction, while HF was not significantly associated with the outcome.

Study context

Population
Post-MI patients; mean (SD) age 62.9 (10.5) years; 24.0% female; 61.2% T2D; 52.1% heart failure (HF)
Participants
26,753 patients5 RCTs4 propensity score-matched (PSM) studies
Comparison
SGLT2 inhibitors vs comparator after myocardial infarction (MI)
Outcome
All-cause mortality
Methodological detailsmeta-regression, stratified analysis (early vs delayed treatment)
  • Meta-regression
  • Stratified analysis (early vs delayed treatment)

Pooled result

As reported in the abstract

Hazard ratio

0.79

95% CI 0.68–0.91

P = 0.001

SGLT2 inhibitorsvs comparator after MI
HR 0.79 (95% CI 0.68–0.91); P = 0.001

Further pooled results

All-cause mortality, early treatment (SGLT2i within 8 weeks post-MI)

Early treatment: consistent effect
HR 0.76, 95% CI [0.59, 0.98]; p = 0.03; I2 = 65%
  • Stratified analysis
  • 16,165 (60.4%) patients

All-cause mortality, delayed treatment

Delayed treatment: consistent effect
HR 0.81, 95% CI [0.67, 0.98]; p = 0.03; I2 = 60%
  • Stratified analysis
  • 10,588 (39.6%) patients

Moderators of mortality benefit (meta-regression)

T2DM a significant moderator of the mortality benefit
β = - 0.0049; p = 0.0006

Original publication

Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis. Cardiovasc Diabetol. Published 22 January 2025. doi:10.1186/s12933-025-02592-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.